caa a22 4500 465789560 CHVBK 20180323112019.0 cr unu---uuuuu 170327e19900801xx s 000 0 eng 10.1007/BF00171834 doi (NATIONALLICENCE)springer-10.1007/BF00171834 Activity of datelliptium acetate (NSC 311152; SR 95156A) against solid tumors of mice [Elektronische Daten] [Patricia Mucci-LoRusso, Lisa Polin, Laura Biernat, Frederick Valeriote, Thomas Corbett] Summary: Datelliptium acetate (NSC 311152) is a water soluble analogue of ellipticine. It is a solid tumor selective compound. In vitro, in a disk diffusion, soft agar colony formation assay (25 ug/disk), the compound demonstrated solid tumor selectivity (compared to leukemia L1210) against colon adenocarcinoma 38 and pancreas ductal carcinoma 03. Upon intravenous administration, NSC 311152 was effective in vivo against a variety of murine solid tumors. Responses at maximum tolerated doses were: colon #07/A (T/C = 33%; 0.60 log cell kill), #38 ((T/C = 0%; 4.2 log cell kill), colon #51/A (T/C = 2%; 1.2 log cell kill), undifferentiated colon #26/A (T/C = 38%; 0.4 log kill), mammary #16/C (T/C = 10%; 1.7 log cell kill), and pancreatic ductal carcinoma #03 (T/C = 0%; 80% cures through day 38). It was ineffective against pancreas #02 (T/C = 45%), mammary 17/A (T/C = 53%), and 17/A/ADR (T/C = 52%). At efficacious doses acute neurotoxicity (i.e. stupor and lethargy) and weight loss were noted (with rapid recovery from both toxicities). There were no delayed toxicities. The agent was slightly necrotizing and produced pain on SC injections. In lieu of its preclinical efficacy and toxicity profiles, we recommend further clinical investigation of this agent. Kluwer Academic Publishers, 1990 datelliptium acetate nationallicence NSC 311152 nationallicence ellipticine nationallicence SR 95156A nationallicence Mucci-LoRusso Patricia Division of Hematology and Oncology, Department of Medicine, Wayne State University School of Medicine, 48201, Detroit, MI, USA aut Polin Lisa Division of Hematology and Oncology, Department of Medicine, Wayne State University School of Medicine, 48201, Detroit, MI, USA aut Biernat Laura Division of Hematology and Oncology, Department of Medicine, Wayne State University School of Medicine, 48201, Detroit, MI, USA aut Valeriote Frederick Division of Hematology and Oncology, Department of Medicine, Wayne State University School of Medicine, 48201, Detroit, MI, USA aut Corbett Thomas Division of Hematology and Oncology, Department of Medicine, Wayne State University School of Medicine, 48201, Detroit, MI, USA aut Investigational New Drugs Kluwer Academic Publishers 8/3(1990-08-01), 253-261 0167-6997 8:3<253 1990 8 10637 https://doi.org/10.1007/BF00171834 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00171834 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Mucci-LoRusso Patricia Division of Hematology and Oncology, Department of Medicine, Wayne State University School of Medicine, 48201, Detroit, MI, USA aut NATIONALLICENCE 700 1- Polin Lisa Division of Hematology and Oncology, Department of Medicine, Wayne State University School of Medicine, 48201, Detroit, MI, USA aut NATIONALLICENCE 700 1- Biernat Laura Division of Hematology and Oncology, Department of Medicine, Wayne State University School of Medicine, 48201, Detroit, MI, USA aut NATIONALLICENCE 700 1- Valeriote Frederick Division of Hematology and Oncology, Department of Medicine, Wayne State University School of Medicine, 48201, Detroit, MI, USA aut NATIONALLICENCE 700 1- Corbett Thomas Division of Hematology and Oncology, Department of Medicine, Wayne State University School of Medicine, 48201, Detroit, MI, USA aut NATIONALLICENCE 773 0- Investigational New Drugs Kluwer Academic Publishers 8/3(1990-08-01), 253-261 0167-6997 8:3<253 1990 8 10637 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer